Zoetis Inc.

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

What Makes Zoetis (ZTS) an Investment Bet?

AI-generated analysis

πŸ’° Diamond Hill Mid Strategy returned 3.65% in Q4 2025, outperforming the Russell Mid Cap Index's 0.16%.

πŸ₯ Zoetis is a leader in animal health with products for companion animals and livestock.

πŸ“‰ The stock closed at $121.68 per share on March 17, 2026, down 5.77% in the past month.

⚠️ Shares lost 25.69% over the past twelve months amid concerns about a specific dog arthritis drug.

πŸ’Ό Diamond Hill views Zoetis as undervalued after recent price pressure created an entry opportunity.

🧬 The company has a broad portfolio with multiple growth drivers and a strong pipeline for undertreated pet conditions.

πŸ“‰ 69 hedge fund portfolios held Zoetis at the end of Q4 2025, down slightly from 72 in the previous quarter.

πŸ€– Diamond Hill prioritizes AI stocks over Zoetis due to perceived higher return potential and shorter timeframes.

🚫 Zoetis is not included on their list of 40 Most Popular Stocks for the upcoming year.

πŸ“Š The market capitalization of Zoetis is approximately $53.6 billion as of early March 2026.

Bullish Signals
  • Diamond Hill Capital's Mid Strategy holds Zoetis Inc. (NYSE: ZTS) as a top five holding, indicating strong institutional confidence in the company.
  • Zoetis is recognized as a leader in the animal health market with leading products for companion animals and livestock, offering multiple growth drivers.
  • The company has a broad portfolio with a strong pipeline designed to address several undertreated pet conditions, providing clear upside potential.
  • Recent share price pressure due to concerns about an arthritis drug has created an entry opportunity at below intrinsic value for the Strategy.
  • Zoetis maintains a substantial market capitalization of approximately $53.624 billion, demonstrating its established market position.
Risk Factors
  • Zoetis Inc. (NYSE: ZTS) stock closed at $121.68 per share, down -5.77% in the past month and losing 25.69% over the past twelve months.
  • Concerns about one of its arthritis drugs used in dogs have pressured the share price recently, indicating specific product-level headwinds.
  • Diamond Hill Mid Strategy is not recommending Zoetis as a top AI investment, stating that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame.
  • Zoetis Inc. (NYSE: ZTS) is not on the list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026, signaling a lack of institutional enthusiasm.
  • Hedge fund interest in Zoetis has declined to 69 portfolios holding the stock at the end of Q4 2025, down from 72 in the previous quarter.
Full Analysis
Diamond Hill Capital released its fourth-quarter 2025 investor letter in March 2026, highlighting Zoetis Inc. (NYSE: ZTS) as one of its key selections within the Diamond Hill Mid Strategy portfolio. The firm noted that while large and small-cap equities posted favorable gains in Q4, with returns of 2.41% and 2.19% respectively, the mid-cap range was a relative laggard, with the Russell Mid Cap Index returning only 0.16%. Despite this broader market context, the Diamond Hill Mid Strategy returned 3.65% net in Q4, significantly outperforming the index, and posted a year-to-date return of 13.47% compared to the Russell Midcap Index's 10.60%. The strategy manager expressed bullish views on Zoetis, describing it as a market leader with products for both companion animals and livestock that offers multiple growth drivers and a strong pipeline for under-treated pet conditions. The firm indicated that recent share price pressure due to concerns over one of its arthritis drugs used in dogs created an opportunity to enter the position below the company's estimated intrinsic value. However, specific stock data points out a -5.77% return over the past month and a 25.69% decline over the past twelve months as of the March 17, 2026 closing price of $121.68 per share. The company maintains a market capitalization of approximately $53.624 billion. While Diamond Hill Capital holds a position in Zoetis, they noted that the stock was not included in their list of the 40 Most Popular Stocks Among Hedge Funds heading into 2026. Data shows that hedge fund portfolios holding Zoetis decreased slightly to 69 at the end of Q4 2025 from 72 in the previous quarter. In its investor letter, Diamond Hill Capital stated that while they acknowledge the risk and potential of ZTS as an investment, their conviction lies with AI stocks, which they believe hold greater promise for delivering higher returns within a shorter time frame. The article also points readers toward additional resources, including Jensen Quality Growth Equity Strategy's views on the company and related articles discussing Zoetis's recent Q3 performance and other analyst ratings like Barclays maintaining a Hold position.